From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Structural basis for inhibition of TSLP-signaling by Tezepelumab.png
Structural basis for inhibition of TSLP-signaling by Tezepelumab (PDB 5J13)[1]
Monoclonal antibody
TypeWhole antibody
Clinical data
SynonymsMEDI9929, AMG 157
Routes of
Subcutaneous injection
ATC code
  • none
Legal status
Legal status
  • Investigational
CAS Number
  • none
Chemical and physical data
Molar mass144.6 kDa g·mol−1

Tezepelumab (INN; development codes MEDI9929 and AMG 157) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis.[2][3] It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.[4]

This drug is being developed in collaboration by MedImmune, LLC and Amgen.

It is in Phase III trials as of October 2018.

Structural studies by X-ray crystallography showed that Tezepelumab competes against a critical part of the TSLPR binding site on TSLP[1]


  1. ^ a b Verstraete, Kenneth; Peelman, Frank; Braun, Harald; Lopez, Juan; Van Rompaey, Dries; Dansercoer, Ann; Vandenberghe, Isabel; Pauwels, Kris; Tavernier, Jan (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1). doi:10.1038/ncomms14937. ISSN 2041-1723. PMC 5382266. PMID 28368013.
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tezepelumab, American Medical Association.
  3. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
  4. ^ Tezepelumab granted Breakthrough Therapy Designation by US FDA - AstraZeneca Press Release